Konstantinidou Eleni I, Kontekaki Eftychia G, Kefas Aristidis, Konstantinidis Theocharis, Romanidou Gioulia, Fotiadou Eleni, Rekari Viki, Triantafyllidou Eleni, Zisaki Stavroula, Kasmeridou Evi, Andreadou Mariana, Kantartzi Konstantina, Mavromatidis Konstantinos, Martinis George, Cassimos Dimitrios, Thodis Elias, Panopoulou Maria, Mimidis Konstantinos
MD, MSc in "Infectious Diseases - International Medicine, From Bench to Bedside", Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis, Greece.
MD, MSc in "Infectious Diseases - International Medicine, From Bench to Bedside", Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis, Greece, Blood Transfusion Center, University General Hospital of Alexandroupolis Dragana Campus, 68100 Alexandroupolis, Greece.
Germs. 2021 Mar 15;11(1):52-58. doi: 10.18683/germs.2021.1240. eCollection 2021 Mar.
HCV infection in patients under hemodialysis for end stage chronic kidney disease (ESCKD) may exist despite the absence of anti-HCV antibodies. Molecular methods are widely accepted as "gold standard" techniques for the detection of viral RNA. However, the molecular methods are more expensive in comparison to conventional methods and their replacement is not cost-effective. The aim of this study was to estimate the prevalence of HCV RNA positivity in anti-HCV negative hemodialysis patients and evaluate new diagnostic methods for the detection and the monitoring of hepatitis C in ESCKD patients.
The study was performed in four hospitals of Thrace region of Greece and 233 patients with no history of hepatitis C were enrolled. Measurement of anti-HCV antibodies and HCV core antigen was performed by microparticle chemiluminescence immunoassay. Molecular detection of viral RNA was performed by the real-time RT PCR.
The mean age of the patients was 64.9 ± 23.3 years. HCV-Ag was positive in 2/233 patients (0.86%). Nevertheless, viral RNA was negative in those patients.
The results of the present study showed that the incidence of HCV-RNA in patients with negative anti-HCV Abs, in hemodialysis patients in Thrace region of Greece was negligible (0/233).
对于终末期慢性肾病（ESCKD）接受血液透析的患者，即使没有抗丙型肝炎病毒（HCV）抗体，也可能存在HCV感染。分子方法被广泛认为是检测病毒RNA的“金标准”技术。然而，与传统方法相比，分子方法成本更高，用其替代传统方法并不划算。本研究的目的是估计抗HCV阴性血液透析患者中HCV RNA阳性的患病率，并评估用于检测和监测ESCKD患者丙型肝炎的新诊断方法。
本研究在希腊色雷斯地区的四家医院进行，纳入了233例无丙型肝炎病史的患者。采用微粒化学发光免疫分析法检测抗HCV抗体和HCV核心抗原。通过实时逆转录聚合酶链反应进行病毒RNA的分子检测。
患者的平均年龄为64.9±23.3岁。233例患者中有2例（0.86%）HCV-Ag呈阳性。然而，这些患者的病毒RNA呈阴性。
本研究结果表明，在希腊色雷斯地区的血液透析患者中，抗HCV抗体阴性患者的HCV-RNA发生率可忽略不计（0/233）。
